$0.61
4.95% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

CytomX Therapeutics, Inc. Stock price

$0.61
-0.04 6.40% 1M
-0.54 47.07% 6M
-0.42 40.90% YTD
-1.53 71.56% 1Y
-2.28 78.94% 3Y
-6.86 91.85% 5Y
-12.29 95.28% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.03 4.95%
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

Key metrics

Market capitalization $46.46m
Enterprise Value $-44.77m
P/E (TTM) P/E ratio 1.48
EV/FCF (TTM) EV/FCF 0.52
EV/Sales (TTM) EV/Sales -0.32
P/S ratio (TTM) P/S ratio 0.34
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 36.45%
Revenue (TTM) Revenue $138.10m
EBIT (operating result TTM) EBIT $25.00m
Free Cash Flow (TTM) Free Cash Flow $-86.54m
Cash position $100.62m
EPS (TTM) EPS $0.39
P/E forward 53.55
P/S forward 0.46
EV/Sales forward negative
Short interest 11.32%
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CytomX Therapeutics, Inc. forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
67%
Hold
33%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
138 138
36% 36%
100%
- Direct Costs 1.77 1.77
64% 64%
1%
136 136
42% 42%
99%
- Selling and Administrative Expenses 28 28
41% 41%
20%
- Research and Development Expense 82 82
17% 17%
59%
27 27
316% 316%
19%
- Depreciation and Amortization 1.77 1.77
64% 64%
1%
EBIT (Operating Income) EBIT 25 25
1,582% 1,582%
18%
Net Profit 32 32
5,691% 5,691%
23%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
27 days ago
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants Roger Song - Jefferies Joe Catanzaro - Piper Sandler Anupam Rama - JPMorgan Peter Lawson - Barclays Operator Good afternoon, everyone. Thank you for standing by.
Neutral
GlobeNewsWire
27 days ago
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -
Neutral
GlobeNewsWire
28 days ago
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 121
Founded 2010
Website www.cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today